Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4515)
All Articles published online
|
Publishing Process of This Article
|
Dec 24, 2020 (publication date) through Jun 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Stuckey R, López-Rodríguez JF, Sánchez-Sosa S, Segura-Díaz A, Sánchez-Farías N, Bilbao-Sieyro C, Gómez-Casares MT. Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. World J Clin Oncol 2020; 11(12): 996-1007 [PMID: 33437662 DOI: 10.5306/wjco.v11.i12.996] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v11/i12/996.htm |
| Number | Citing Articles |
| 1 |
Ruth Stuckey, Juan Francisco López Rodríguez, María Teresa Gómez-Casares. Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission. Current Oncology Reports 2022; 24(4): 415 doi: 10.1007/s11912-022-01228-w
|
| 2 |
Tim H. Brümmendorf, Jorge E. Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E. Clark, Philipp le Coutre, Valentin Garcia-Gutierrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 2022; 36(7): 1825 doi: 10.1038/s41375-022-01589-y
|
| 3 |
Ine Schmale. Chronische myeloische Leukämie. Onkologische Welt 2021; 12(03): 174 doi: 10.1055/a-1500-1909
|
| 4 |
Jie Tian, Yong-Ping Song, Gao-Chong Zhang, Shu-Fang Wang, Xiao-Xiang Chu, Ye Chai, Chun-Ling Wang, Ai-Li He, Feng Zhang, Xu-Liang Shen, Wei-Hua Zhang, Lin-Hua Yang, Da-Nian Nie, Dong-Mei Wang, Huan-Ling Zhu, Da Gao, Shi-Feng Lou, Ze-Ping Zhou, Guo-Hong Su, Yan Li, Jin-Ying Lin, Qing-Zhi Shi, Gui-Fang Ouyang, Hong-Mei Jing, Sai-Juan Chen, Jian Li, Jian-Qing Mi. Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes. Journal of Cancer Research and Clinical Oncology 2024; 150(4) doi: 10.1007/s00432-024-05700-x
|
| 5 |
María Nieves Saez Perdomo, Ruth Stuckey, Elena González-Pérez, Santiago Sánchez-Sosa, Paula Estupiñan-Cabrera, Sunil Lakhwani Lakhwani, José David González San Miguel, Nuria Hernanz Soler, Marina Gordillo, Gloria González Brito, María Tapia-Torres, Ana Ruano, Adrián Segura-Díaz, Hugo Luzardo, Cristina Bilbao-Sieyro, María Teresa Gómez-Casares. The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia. Hematology Reports 2024; 16(1): 140 doi: 10.3390/hematolrep16010015
|
| 6 |
Marco Pizzi, Carmela Gurrieri, Attilio Orazi. What’s New in the Classification, Diagnosis and Therapy of Myeloid Leukemias. Hemato 2023; 4(2): 112 doi: 10.3390/hemato4020011
|